4.3 Review

Venetoclax in Acute Myeloid Leukemia

Journal

RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY
Volume 18, Issue 1, Pages 11-28

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1574892817666220429105338

Keywords

Acute myeloid leukemia; apoptosis; BCL-2; hypomethylating agent; minimal residual disease; myelodysplastic syndrome; tumor lysis syndrome; venetoclax

Ask authors/readers for more resources

This study analyzed the efficacy and safety of venetoclax in the treatment of acute myeloid leukemia. The results showed that venetoclax-based combinations were able to improve outcomes for older patients, including remission rates and overall survival. However, venetoclax resistance and adverse effects should also be taken into consideration.
Background: Substantial progress in the therapeutic arsenal used to treat acute myeloid leukemia became possible in the last decade, as a result of advances in gene editing and descriptive and functional genomics. Objective: The aim of this study is to analyze the efficacy and safety of venetoclax in the treatment of acute myeloid leukemia. Methods: A mini-review was achieved using the articles published in PubMed and Web of Science in the last year, prior to 05.05.2021, which were searched using the terms acute myeloid leukemia and venetoclax and the new patents published in this field. Results: BCL-2 inhibitors administered in monotherapy are active against acute myeloid leukemia cells, but their efficacy is partially limited because they do not target other antiapoptotic proteins and venetoclax induced overexpression of the other antiapoptotic molecules. Venetoclax-based combinations (including those with hypomethylating agents) were able to improve outcomes for older patients with acute myeloid leukemia, including both remission rates and overall survival. Other drugs used in combination with venetoclax include: FLT3 inhibitors, IDH2 inhibitors, chidamide, ibrutinib, lapatinib, mivebresib, triptolide, metabolic inhibitors, nucleoside analogs, and classical chemotherapeutics. Both the mechanisms of venetoclax resistance and the ways to overcome it, as well as the adverse effects of venetoclax are analyzed. Conclusion: The management of unfit and older patients with acute myeloid leukemia should be personalized and be the result of evaluating patient- and disease-specific factors that are essential to their care. Combinations that include venetoclax are an increasingly well-documented option for many of them.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available